Chordate Medical Holding AB (publ) (CMH.ST)
SEK 5.32
(8.65%)
SEK 5.32
(8.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -28.41 Million SEK | -87089.39% |
| 2022 | 34.06 Thousand SEK | -98.23% |
| 2021 | 1.92 Million SEK | -23.43% |
| 2020 | 2.51 Million SEK | 21.38% |
| 2019 | 2.07 Million SEK | 4580.14% |
| 2018 | -46.23 Thousand SEK | -108.69% |
| 2017 | 531.82 Thousand SEK | 33.22% |
| 2016 | 399.21 Thousand SEK | 55.54% |
| 2015 | 256.67 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -6.01 Million SEK | 39.89% |
| 2024 Q2 | 1.06 Million SEK | 117.78% |
| 2023 Q4 | -10 Million SEK | -2066.2% |
| 2023 Q1 | 93.58 Thousand SEK | 2548.16% |
| 2023 Q3 | 509.02 Thousand SEK | 27.29% |
| 2023 Q2 | 399.88 Thousand SEK | 327.29% |
| 2023 FY | -29.63 Million SEK | -87089.39% |
| 2022 Q1 | 14.24 Thousand SEK | -96.06% |
| 2022 FY | 34.06 Thousand SEK | -98.23% |
| 2022 Q4 | 3534.00 SEK | 100.58% |
| 2022 Q3 | -613.31 Thousand SEK | -3865.88% |
| 2022 Q2 | 16.28 Thousand SEK | 14.34% |
| 2021 FY | 1.92 Million SEK | -23.43% |
| 2021 Q1 | 273.74 Thousand SEK | -40.21% |
| 2021 Q2 | 844.42 Thousand SEK | 208.47% |
| 2021 Q3 | 445.29 Thousand SEK | -47.27% |
| 2021 Q4 | 361.86 Thousand SEK | -18.74% |
| 2020 Q1 | 829.17 Thousand SEK | -52.92% |
| 2020 Q4 | 457.83 Thousand SEK | -11.58% |
| 2020 FY | 2.51 Million SEK | 21.38% |
| 2020 Q3 | 517.8 Thousand SEK | -27.02% |
| 2020 Q2 | 709.52 Thousand SEK | -14.43% |
| 2019 FY | 2.07 Million SEK | 4580.14% |
| 2019 Q1 | -32.58 Thousand SEK | 96.65% |
| 2019 Q2 | 158.33 Thousand SEK | 585.93% |
| 2019 Q3 | 184.48 Thousand SEK | 16.52% |
| 2019 Q4 | 1.76 Million SEK | 854.66% |
| 2018 Q3 | 459.31 Thousand SEK | 111.77% |
| 2018 FY | -46.23 Thousand SEK | -108.69% |
| 2018 Q2 | 216.89 Thousand SEK | 822.63% |
| 2018 Q1 | -30.01 Thousand SEK | -166.3% |
| 2018 Q4 | -971.19 Thousand SEK | -311.44% |
| 2017 Q1 | 649.99 Thousand SEK | -10.06% |
| 2017 FY | 531.82 Thousand SEK | 33.22% |
| 2017 Q2 | 241.11 Thousand SEK | -62.91% |
| 2017 Q3 | -404.55 Thousand SEK | -267.79% |
| 2017 Q4 | 45.27 Thousand SEK | 111.19% |
| 2016 Q3 | 227.49 Thousand SEK | 459.78% |
| 2016 Q2 | -63.23 Thousand SEK | 0.0% |
| 2016 FY | 399.21 Thousand SEK | 55.54% |
| 2016 Q4 | 722.67 Thousand SEK | 217.67% |
| 2015 FY | 256.67 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | 636.418% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 109.452% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 109.452% |
| Arcoma AB | 11.07 Million SEK | 356.653% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 120.299% |
| BICO Group AB (publ) | 1.83 Billion SEK | 101.552% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 111.379% |
| CellaVision AB (publ) | 463.04 Million SEK | 106.136% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | 1048.084% |
| C-Rad AB (publ) | 66.01 Million SEK | 143.042% |
| Duearity AB (publ) | -4.17 Million SEK | -580.088% |
| Dignitana AB (publ) | 58.97 Million SEK | 148.183% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 32.024% |
| Getinge AB (publ) | 13.43 Billion SEK | 100.212% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 43.418% |
| Iconovo AB (publ) | 17.57 Million SEK | 261.649% |
| Integrum AB (publ) | 690.56 Thousand SEK | 4214.631% |
| Luxbright AB (publ) | -2.79 Million SEK | -915.922% |
| Mentice AB (publ) | 236.38 Million SEK | 112.02% |
| OssDsign AB (publ) | 83.64 Million SEK | 133.97% |
| Paxman AB (publ) | 12.61 Million SEK | 325.187% |
| Promimic AB (publ) | 38.51 Million SEK | 173.774% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 44.015% |
| SciBase Holding AB (publ) | 16.03 Million SEK | 277.178% |
| ScandiDos AB (publ) | 47.55 Million SEK | 159.75% |
| Sectra AB (publ) | 557.55 Million SEK | 105.096% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 126.073% |
| Senzime AB (publ) | 8.33 Million SEK | 440.737% |
| SpectraCure AB (publ) | -9.22 Million SEK | -208.078% |
| Stille AB | 132.17 Million SEK | 121.498% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 101.437% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 106.815% |